Already riding naloxone boom, Amphastar plots nasal spray to rival old formulas

A surge of opioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidote naloxone. The drug's price has risen tenfold in recent years, Bloomberg reports, and state and local governments are shelling out to make it more widely available. One beneficiary? Amphastar Pharmaceuticals ($AMPH), which saw a 41% Q2 boost in revenue from its fully manufactured drugs. And the company is developing a ready-made naloxone nasal spray it hopes will pad its top line further. More

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.